Annual Total Long Term Liabilities
$98.87 M
-$11.49 M-10.41%
December 31, 2023
Summary
- As of February 7, 2025, PSTX annual total long term liabilities is $98.87 million, with the most recent change of -$11.49 million (-10.41%) on December 31, 2023.
- During the last 3 years, PSTX annual total long term liabilities has risen by +$19.38 million (+24.37%).
Performance
PSTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Long Term Liabilities
$128.10 M
-$7.34 M-5.42%
September 30, 2024
Summary
- As of February 7, 2025, PSTX quarterly total long term liabilities is $128.10 million, with the most recent change of -$7.34 million (-5.42%) on September 30, 2024.
- Over the past year, PSTX quarterly long term liabilities has dropped by -$7.34 million (-5.42%).
Performance
PSTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PSTX Long Term Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -10.4% | -5.4% |
3 y3 years | +24.4% | +60.2% |
5 y5 years | -9.1% | - |
PSTX Long Term Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -10.4% | -29.4% | -5.4% | -45.5% |
5 y | 5-year | -64.0% | -29.4% | -68.2% | -45.8% |
alltime | all time | -64.0% | -47.7% | -68.2% | -45.8% |
Poseida Therapeutics Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $128.10 M(-5.4%) |
Jun 2024 | - | $135.44 M(+45.3%) |
Mar 2024 | - | $93.22 M(-5.7%) |
Dec 2023 | $98.87 M(-10.4%) | $98.87 M(-2.7%) |
Sep 2023 | - | $101.62 M(+5.8%) |
Jun 2023 | - | $96.03 M(-10.6%) |
Mar 2023 | - | $107.37 M(-2.7%) |
Dec 2022 | $110.36 M(+58.2%) | $110.36 M(-4.2%) |
Sep 2022 | - | $115.20 M(+15.7%) |
Jun 2022 | - | $99.56 M(-1.0%) |
Mar 2022 | - | $100.53 M(+44.1%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2021 | $69.76 M(-12.2%) | $69.76 M(-12.8%) |
Sep 2021 | - | $79.98 M(-0.7%) |
Jun 2021 | - | $80.54 M(+3.2%) |
Mar 2021 | - | $78.06 M(-1.8%) |
Dec 2020 | $79.49 M(-71.1%) | $79.49 M(-0.1%) |
Sep 2020 | - | $79.56 M(-80.2%) |
Jun 2020 | - | $402.76 M(+480.3%) |
Mar 2020 | - | $69.41 M(-74.7%) |
Dec 2019 | $274.65 M(+152.4%) | $274.65 M |
Dec 2018 | $108.81 M(+110.3%) | - |
Dec 2017 | $51.75 M | - |
FAQ
- What is Poseida Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Poseida Therapeutics?
- What is Poseida Therapeutics annual total long term liabilities year-on-year change?
- What is Poseida Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly long term liabilities year-on-year change?
What is Poseida Therapeutics annual total long term liabilities?
The current annual total long term liabilities of PSTX is $98.87 M
What is the all time high annual total long term liabilities for Poseida Therapeutics?
Poseida Therapeutics all-time high annual total long term liabilities is $274.65 M
What is Poseida Therapeutics annual total long term liabilities year-on-year change?
Over the past year, PSTX annual total long term liabilities has changed by -$11.49 M (-10.41%)
What is Poseida Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of PSTX is $128.10 M
What is the all time high quarterly long term liabilities for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly total long term liabilities is $402.76 M
What is Poseida Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, PSTX quarterly total long term liabilities has changed by -$7.34 M (-5.42%)